Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma.

Katharina KriegsmannMichael RiegerMark-Alexander SchwarzbichSören SitterMark KriegsmannThomas BrucknerManfred HenselAnthony Dick HoMathias Witzens-HarigPatrick Wuchter

Published in: European journal of haematology (2018)

HDT and ABSCT directly after induction chemotherapy were confirmed to be feasible with high PFS and OS rates. In addition, for patients with relapse after first-line therapy and consecutively poor prognosis, HDT/ABSCT also offers an effective treatment strategy.

Keyphrases

high dose
stem cell transplantation
poor prognosis
long non coding rna
low dose
locally advanced
cell therapy
squamous cell carcinoma
bone marrow
stem cells
hodgkin lymphoma
radiation therapy
mesenchymal stem cells
free survival
replacement therapy